83North, Marathon Capital back Lenses.io
Venture capital investors 83North and Marathon Capital have invested $7.5m in a series-A round for UK and Greece-based data and analytics services specialist Lenses.io.
83North is currently investing via its 83 North IV fund, closed on $250m in 2017.
Marathon provides seed rounds investing €500,000-1m in exchange for 15-20% of equity, and then eventually follows up in series-A stage.
The fresh capital will be used for product development, and to scale the company in Europe and in the US. Lenses launched its flagship DataOps product in early 2018.
The business first received seed funding from Marathon Capital last year.
Company
Lenses.io's DataOps product manages processes and technology that build and enhance data pipelines to better meet business needs. For example, the product brings together data consumers in a unified experience, enabling rapid, code-free visibility into data systems. Current customers include Babylon Health, Daimler, Zopa, Playtika and SAS Software.
The startup was founded in 2016 and is based in both in London and Athens.
People
Lenses.io – Antonios Chalkiopoulous (founder).
More on Expansion
Xerys, Siparex et al. close $18.6m series-B for Herow
Backers close a $18.6m round started in 2015 with an initial $10.6m capital injection
Nordic Capital's Acino acquires Takeda's primary care portfolio
Coller Capital and Goldman Sachs acquired a stake in Acino in 2018 in a GP-led secondary transaction
Ahren et al. in $16m round for Mogrify
Biotech's series-A is supported by a consortium of investors led by existing backer Ahren
Tenzing invests in Eikon
YFM Private Equity made a growth investment in the digital post-production company last year
Latest News
Xerys, Siparex et al. close $18.6m series-B for Herow
Backers close a $18.6m round started in 2015 with an initial $10.6m capital injection
Nordic Capital acquires iLoq from Sievi Capital for €190m
GP invests via its Nordic Capital Fund IX, which held a final close on €4.3bn in May 2018
BIVF, Gründerfonds Ruhr lead €12m series-A round for Abalos
Abalos Therapeutics is a biotechnology company focused on developing immuno-oncology therapeutics
Arx buys TES Vsetin from Advent
Existing management team will lead the company's future growth and development
